Howard Liebman, MD

Professor of Medicine and Pathology

Donald I. Feinstein, MD, Chair in Hematology

Is this your profile? Click to edit

Overview

Dr. Howard Liebman, Professor of Medicine and Pathology is the author or co-author of over 170 peer reviewed publications, review articles and chapters. He has presented over two hundred lectures across the United States, South America, Europe. Korea and Japan. He has served as the former Chair of the Massachusetts Governor’s Task Force subcommittee on experimental therapies and clinical trials for AIDS. He is a medical advisor for the Platelet Disorder Support Association and a member of the Cancer and Thrombosis Guidelines Committee of the American Society of Clinical Oncology. He has served on several grant review committees for the National Institute of Health. He presently holds the Donald I Feinstein Endowed Chair of Hematology.

In addition to his academic responsibilities, Dr. Liebman is an attending staff member of the LAC+USC Medical Center, the USC/Norris Comprehensive Cancer Center and the Keck Hospital of USC. Dr. Liebman also is on the forefront of research in thrombotic and hemorrhagic disorders. His lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, and arterial thrombosis. Dr. Liebman is also internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy. He has been and is the principal investigator on several clinical trials in the management of immune thrombocytopenia (ITP). His research group has made important discoveries on the role of infectious agents in the development of immune thrombocytopenia and secondary ITP.

Awards

American College of Physicians: Fellow

Education and Training

Keck School of Medicine — MD — Medical School, Doctor of Medicine
LAC + USC Medical Center — Internship, Internal Medicine
LAC + USC Medical Center — Residency, Internal Medicine
LAC + USC Medical Center — Fellowship, Hematology
Tufts-New England Medical Center — Fellowship in Immunochemistry and coagulation chemistry

Research Funding

ROLE OF METAL IONS IN THE FUNCTION OF HUMAN FACTOR IX
NIH · R29HL039665 · Feb 15, 1988 – Mar 1, 1994 · Role: Principal Investigator

Publications

A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood. 2007 Jun 15; 109(12):5527.. View in PubMed
Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006 Oct 20; 24(30):4928-32.. View in PubMed
Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr. 2006 Aug 15; 42(5):572-7.. View in PubMed
Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006 Feb; 33(2):355-7.. View in PubMed
Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control. 2005 Sep; 12.. View in PubMed
Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005 Jun; 129(6):818-24.. View in PubMed
Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res. 2005 Mar; 29(3):347-51.. View in PubMed
Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases. Clin Adv Hematol Oncol. 2004 Jun; 2(6):382-4.. View in PubMed
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003 Oct; 123(2):278-81.. View in PubMed
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003 Jan; 72(1):43-52.. View in PubMed